Abstract
Multiple sclerosis (MS) is an inflammatory and demyelinating disease of the central nervous system (CNS) that results in variable severities of neurodegeneration. The understanding of MS has been limited by the inaccessibility of the affected cells and the lengthy timeframe of disease development. However, recent advances in stem cell technology have facilitated the bypassing of some of these challenges. Towards gaining a greater understanding of the innate potential of stem cells from people with varying degrees of disability, we generated induced pluripotent stem cells (iPSCs) from peripheral blood mononuclear cells derived from stable and progressive MS patients, and then further differentiated them into oligodendrocyte (OL) lineage cells. We analyzed differentiation under both homeostatic and inflammatory conditions via sustained exposure to low-dose interferon gamma (IFNγ), a prominent cytokine in MS. We found that all iPSC lines differentiated into mature myelinating OLs, but chronic exposure to IFNγ dramatically inhibited differentiation in both MS groups, particularly if exposure was initiated during the pre-progenitor stage. Low-dose IFNγ was not toxic but led to an early upregulation of interferon response genes in OPCs followed by an apparent redirection in lineage commitment from OL to a neuron-like phenotype in a significant portion of the treated cells. Our results reveal that a chronic low-grade inflammatory environment may have profound effects on the efficacy of regenerative therapies.
Highlights
IPSCs from people with Multiple sclerosis (MS) can differentiate into oligodendrocytes in homeostatis but not inflammation
peripheral blood mononuclear cells (PBMCs)-derived induced pluripotent stem cells (iPSCs) were validated as described in methods and cultured under a standard protocol to generate OL lineage cells
The results of our studies revealed a number of novel and intriguing findings that may help to advance the development of strategies for neuroprotection and/or repair
Summary
For OPCs to contribute to remyelination, they likely must migrate to the sites of injury, proliferate, and differentiate into OLs [10]. Each of these processes can be inhibited by cytokines (e.g., IL-6, IL-17, osteopontin, IFNγ, TNFα), chemokines (e.g., CXCL1, CXCL2, CXCL10, CXCL11), cytolytic proteins (e.g., lymphotoxin-a and perforin), and signaling factors (e.g., astrocyte-derived endothelin-1 (ET-1), all of which are known to be present at demyelinated areas [11,12,13,14,15,16], thereby establishing a potentially challenging environment for repair
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.